article thumbnail

Regenerative medicine: new focus on VEGF target?

Pharmaceutical Technology

Regenerative medicines in early-stage development (preclinical, discovery, or investigational new drug [IND]/ clinical trial application [CTA] filed status) have seen a change in drug targets compared to therapies in late-stage development (Phase II to pre-registration stage).

Medicine 246
article thumbnail

Nemolizumab Approved for Adults with Prurigo Nodularis

XTalks

The approval marks a huge milestone for nemolizumab, which recently demonstrated significant itch-relief in clinical trials last month in adolescent and adult patients with moderate-to-severe atopic dermatitis. A significant percentage of patients also reported reduced sleep disturbances by Week 16 in both clinical trials.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Digital clinical trials: Trends to watch in 2023

Pharmaceutical Technology

Following the increased use of telemedicine during the Covid-19 pandemic, the potential of digital technologies in communication, data collection, and analysis has become increasingly realised by patients, healthcare systems, and clinical trial sponsors.

article thumbnail

Positive data from two Phase 3 Dupixent® (dupilumab) trials in prurigo nodularis published in Nature Medicine

The Pharma Data

Positive data from two Phase 3 Dupixent ® (dupilumab) trials in prurigo nodularis published in Nature Medicine Positive results from two Phase 3 Dupixent ® (dupilumab) trials in adults with uncontrolled prurigo nodularis have been published in Nature Medicine. Results from the trials were the basis for the U.S.

article thumbnail

US FDA accepts Arcutis’ NDA for seborrheic dermatitis therapy

Pharmaceutical Technology

“If approved, roflumilast foam would be the first topical drug with a new mechanism of action for this condition in over two decades, highlighting the unique formulation and deep dermatological expertise that Arcutis brings to immuno-dermatology.” The findings showed that the trial met its primary endpoint, with a 79.5%

article thumbnail

J&J presents successful data from plaque psoriasis trial  

Drug Discovery World

Johnson & Johnson has announced the first data from FRONTIER 2, the long-term extension of the Phase IIb FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide designed to block the IL-23 receptor. at 16 weeks and 76.2% at 52 weeks). .

Trials 52
article thumbnail

Verrica’s Dr. Lawrence Eichenfield Speaks About FDA Approval of New Drug for Common Skin Infection – Xtalks Life Science Podcast Ep. 121

XTalks

Eichenfield was also the principal investigator on clinical trials evaluating YCANTH. Verrica Pharmaceuticals is a dermatology therapeutics company developing medications for skin diseases that require medical interventions.